Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin

被引：17

作者：

Fabbroni, Chiara ^{[1
]}

Fuca, Giovanni ^{[1
]}

Ligorio, Francesca ^{[1
]}

Fumagalli, Elena ^{[1
]}

Barisella, Marta ^{[2
]}

Collini, Paola ^{[2
]}

Morosi, Carlo ^{[3
]}

Gronchi, Alessandro ^{[4
]}

Dei Tos, Angelo Paolo ^{[5
,6
]}

Casali, Paolo Giovanni ^{[1
,7
]}

Sanfilippo, Roberta ^{[1
]}

机构：

[1] Fdn IRCCS Ist Nazl Tumori, Adult Mesenchymal Tumour Med Oncol Unit, I-20133 Milan, Italy

[2] Fdn IRCCS Ist Nazl Tumori, Dept Pathol, I-20133 Milan, Italy

[3] Fdn IRCCS Ist Nazl Tumori, Dept Radiol, I-20133 Milan, Italy

[4] Fdn IRCCS Ist Nazl Tumori, Dept, I-20133 Milan, Italy

[5] Treviso Gen Hosp, Dept Pathol & Mol Genet, I-31100 Treviso, Italy

[6] Univ Padua, Sch Med, Dept Med, I-35128 Padua, Italy

[7] Univ Milan, Oncol & Hematooncol Dept, I-20122 Milan, Italy

来源：

CANCERS | 2021年 / 13卷 / 06期

关键词：

trabectedin; liposarcoma; grading; soft tissue sarcoma; chemotherapy; SOFT-TISSUE; DIFFERENTIATED LIPOSARCOMA; IFOSFAMIDE; SARCOMAS;

D O I：

10.3390/cancers13061453

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Simple Summary The treatment options for advanced well differentiated liposarcoma (WDLPS) and dedifferentiated liposarcoma (DDLPS) are scant, especially after the failure of first-line, anthracycline-based treatment, when trabectedin is one of the most active agents currently approved. Thus, the identification of biological characteristics allowing an efficient patients stratification in this setting appears mandatory. Here, applying a grading-based stratification, we showed that trabectedin may be more active against low-grade LPS (i.e., WDLPS and low-grade DDLPS) than in high-grade LPS (i.e., high-grade DDLPS). If confirmed, our data might allow the implementation of grading as a tool patients' stratification in this setting. Background. We previously showed that grading can prognosticate the outcome of retroperitoneal liposarcoma (LPS). In the present study, we aimed to explore the impact of pathological stratification using grading on the clinical outcomes of patients with advanced well-differentiated LPS (WDLPS) and dedifferentiated LPS (DDLPS) treated with trabectedin. Patients: We included patients with advanced WDLPS and DDLPS treated with trabectedin at the Fondazione IRCCS Istituto Nazionale dei Tumori between April 2003 and November 2019. Tumors were categorized in WDLPS, low-grade DDLPS, and high-grade DDLPS according to the 2020 WHO classification. Patients were divided in two cohorts: Low-grade (WDLPS/low-grade DDLPS) and high-grade (high-grade DDLPS). Results: A total of 49 patients were included: 17 (35%) in the low-grade cohort and 32 (65%) in the high-grade cohort. Response rate was 47% in the low-grade cohort versus 9.4% in the high-grade cohort (logistic regression p = 0.006). Median progression-free survival (PFS) was 13.7 months in the low-grade cohort and 3.2 months in the high-grade cohort. Grading was confirmed as an independent predictor of PFS in the Cox proportional-hazards regression multivariable model (adjusted hazard ratio low-grade vs. high-grade: 0.45, 95% confidence interval: 0.22-0.94; adjusted p = 0.035). Conclusions: In this retrospective case series, sensitivity to trabectedin was higher in WDLPS/low-grade DDLPS than in high-grade DDLPS. If confirmed in larger series, grading could represent an effective tool to personalize the treatment with trabectedin in patients with advanced LPS.

引用

页码：1 / 10

页数：10

共 23 条

[1]

[Anonymous], 2018, SURG ONCOL CLIN PRAC

[2] Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Casali, P. G. ;

Abecassis, N. ;

Bauer, S. ;

Biagini, R. ;

Bielack, S. ;

Bonvalot, S. ;

Boukovinas, I. ;

Bovee, J. V. M. G. ;

Brodowicz, T. ;

Martin-Broto, J. ;

Buonadonna, A. ;

De Alava, E. ;

Dei Tos, A. P. ;

Del Muro, X. G. ;

Dileo, P. ;

Eriksson, M. ;

Fedenko, A. ;

Ferraresi, V. ;

Ferrari, A. ;

Ferrari, S. ;

Frezza, A. M. ;

Gasperoni, S. ;

Gelderblom, H. ;

Gil, T. ;

Grignani, G. ;

Gronchi, A. ;

Haas, R. L. ;

Hannu, A. ;

Hassan, B. ;

Hohenberger, P. ;

Issels, R. ;

Joensuu, H. ;

Jones, R. L. ;

Judson, I. ;

Jutte, P. ;

Kaal, S. ;

Kasper, B. ;

Kopeckova, K. ;

Krakorova, D. A. ;

Le Cesne, A. ;

Lugowska, I. ;

Merimsky, O. ;

Montemurro, M. ;

Pantaleo, M. A. ;

Piana, R. ;

Picci, P. ;

Piperno-Neumann, S. ;

Pousa, A. L. ;

Reichardt, P. ;

Robinson, M. H. .

ANNALS OF ONCOLOGY, 2018, 29 :51-67

[3] Trabectedin therapy for sarcomas [J].

Casali, Paolo G. ;

Sanfilippo, Roberta ;

D'Incalci, Maurizio .

CURRENT OPINION IN ONCOLOGY, 2010, 22 (04) :342-346

[4] Well-differentiated and dedifferentiated liposarcomas [J].

Coindre, Jean-Michel ;

Pedeutour, Florence ;

Aurias, Alain .

VIRCHOWS ARCHIV, 2010, 456 (02) :167-179

[5] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[6]

Goldblum J., 2013, ENZINGER WEISSS SOFT, V6th, P484

[7] Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study [J].

Grosso, Federica ;

Jones, Robin L. ;

Demetri, George D. ;

Judson, Ian R. ;

Blay, Jean-Yves ;

Le Cesne, Axel ;

Sanfilippo, Roberta ;

Casieri, Paola ;

Collini, Paola ;

Dileo, Palma ;

Spreafico, Carlo ;

Stacchiotti, Silvia ;

Tamborini, Elena ;

Tercero, Juan Carlos ;

Jimeno, Jose ;

D'Incalci, Maurizio ;

Gronchi, Alessandro ;

Fletcher, Jonathan A. ;

Pilotti, Silvana ;

Casali, Paola G. .

LANCET ONCOLOGY, 2007, 8 (07) :595-602

[8] A solution to the problem of separation in logistic regression [J].

Heinze, G ;

Schemper, M .

STATISTICS IN MEDICINE, 2002, 21 (16) :2409-2419

[9] Dedifferentiated liposarcoma - A clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation [J].

Henricks, WH ;

Chu, YC ;

Goldblum, JR ;

Weiss, SW .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1997, 21 (03) :271-281

[10] Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival [J].

Italiano, A. ;

Toulmonde, M. ;

Cioffi, A. ;

Penel, N. ;

Isambert, N. ;

Bompas, E. ;

Duffaud, F. ;

Patrikidou, A. ;

Lortal, B. ;

Le Cesne, A. ;

Blay, J. -Y. ;

Maki, R. G. ;

Schwartz, G. K. ;

Antonescu, C. R. ;

Singer, S. ;

Coindre, J. -M. ;

Bui, B. .

ANNALS OF ONCOLOGY, 2012, 23 (06) :1601-+

← 1 2 3 →